Key biomarkers identified for predicting disability progression in multiple sclerosis

A pioneering study presented at ECTRIMS 2024 has identified critical biomarkers that can predict disability worsening in multiple sclerosis. The breakthrough research has the potential to transform treatment strategies for millions of patients with multiple sclerosis worldwide, paving the way for more personalized and effective treatment plans.

In this multicentre observational study, conducted across 13 hospitals in Spain and Italy, Dr. Enric Monreal and his team found that elevated serum neurofilament light chain (sNfL) levels—a protein indicating nerve cell damage—at the onset of multiple sclerosis can predict both relapse-associated worsening (RAW) and progression independent of relapse activity (PIRA).* Additionally, serum glial fibrillary acidic protein (sGFAP) levels—a protein derived from astrocytes that enters the bloodstream when the central nervous system (CNS) is injured or inflamed—correlate with PIRA in patients with low levels of sNfL.

The study analyzed blood samples from 725 patients with multiple sclerosis collected within 12 months of disease onset. Using the Single Molecule Array (SIMOA) technique, researchers assessed the prognostic value of sNfL and sGFAP levels to predict RAW and PIRA.

Key findings reveal that higher sNfL levels, indicative of acute inflammation within the CNS in multiple sclerosis, are associated with a 45% increased risk of RAW and a 43% increased risk of PIRA. Patients with high sNfL levels often did not respond well to standard disease-modifying treatments (DMTs) but showed significant benefits from high-efficacy DMTs (HE-DMTs) such as Natalizumab, Alemtuzumab, Ocrelizumab, Rituximab, and Ofatumumab.

In contrast, patients with high sGFAP levels—which is an indicator of more localized inflammation driven by microglia in the CNS—and low sNfL levels experienced an 86% increased risk of PIRA. This group did not respond to current DMTs.

Interestingly, while sGFAP is known to be associated with progression,² high sNfL levels limited the ability of sGFAP to predict this outcome. Specifically, sGFAP values were predictive of PIRA only in patients with low sNfL levels.

“The identification of sNfL and sGFAP as predictive biomarkers allows us to tailor treatment strategies for multiple sclerosis patients more effectively,” says Dr. Monreal, researcher in multiple sclerosis at Ramón y Cajal University Hospital and first author of the study. “Patients with low levels of both biomarkers had a good prognosis and could be treated with injectable or oral DMTs. However, high sNfL levels indicate a need for HE-DMTs to prevent disability worsening, while patients with high sGFAP levels and low values of sNfL may require new therapeutic approaches. These distinct pathways in multiple sclerosis have significant therapeutic implications, as current DMTs primarily target the peripheral adaptive immune system without affecting CNS immunity. Therefore, identifying patients with higher levels of peripheral inflammation is crucial for preventing disability and improving patient outcomes."

“The results of this study underscore the critical need for personalized treatment approaches to effectively manage the millions of people affected by multiple sclerosis worldwide, many of whom have chronic disability that significantly impacts their quality of life,” says Dr. Monreal.

“By measuring both sNfL and sGFAP levels at disease onset, we gain valuable insights into the progression pathways of multiple sclerosis, enabling clinicians to identify the optimal patients for specific DMTs. This approach aims to prevent disability while avoiding unnecessary treatment-related risks for those at lower risk."

Source: News Release
ECTRIMS
September 19, 2024